A recent study has shown that anti-PD-L1 antibody therapy failed to inhibit SCC VII tumor growth, but combination treatment with MEK inhibitor and anti-PD-L1 antibody showed a synergistic effect in inhibiting tumor growth [35]. This evidence concerns the gene CD274 and neoplasm.